Generex/Antigen Express Interview on Clear Channel Business Talk Radio DFW 1190AM by Host Michael Yorba
Interview Today, Wed, Feb 12, at 2:15PM EST
WORCESTER, MA and TORONTO, ON–(Feb 12, 2014) – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that Dr. Eric von Hofe, PhD, President of the Company’s wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be interviewed live today on Clear Channel’s business talk radio show “The Traders Network” by host Michael Yorba:
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true
Date: Wednesday, February 12, 2014
Time: 2:15 pm EST (1:15 CST, 11:15 PST)
Network: Clear Channel
Show: The Traders Network
Station: DFW 1190AM
Host: Michael Yorba
The interview will canvass the increasing importance of immunotherapies in the treatment of cancers, and the proprietary Antigen Express vaccine technology, presently in a late Phase II trial in breast cancer patients.
About Clear Channel
Clear Channel Media and Entertainment’s more than 840 radio stations offer programming nationwide. Individual station brands connect with diverse audiences in local markets across the country reaching more than 112 million listeners. www.clearchannel.com.
About Michael Yorba
Mr. Yorba is the founder of Yorba Media and featured host on Clear Channel’s DFW 1190AM in Dallas-Ft. Worth, TX. For the past six years he has been integrally involved with producing and hosting a daily talk show called Commodity Classics, and The Traders Network.
From the fast action of the trading pit… to the power brokers making the headlines… Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, political trends, crowd funding and impact investment insights in a new light and keeps investors and consumers asking for more… The Traders Network stays ahead of the curve by featuring leading market and business professionals, sophisticated technology, and the analytics needed to identify the most lucrative investment strategies. Successful performance depends on finding the right opportunities. So… shift your thinking and join us as we deliver “tomorrow’s ideas today” on Clear Channel’s the Traders Network Monday – Friday from 1:00pm – 3:00pm CST live after Glenn Beck.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Cautionary Note Regarding Forward-Looking Statements
This release, and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any “phase” of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
A CommPro Worldwide PR Event
PR & Media Contact:
Matt Bird, CEO
C: +1 (646) 401-4499